retatrutide triple agonist obesity trial 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 Medscape | Retatrutide, Eli Lilly's

Beyond Weight Loss: Health Benefits That Extend Horizons The significance of Retatrutide reaches beyond shedding pounds

Tirzepatide best result: 22.5% body weight loss over 72 weeks on the 15mg dose, versus 2.4% for placebo

A recent case report suggests that such medications can influence brain regions involved in emotional regulation and potentially trigger or worsen severe depressive symptoms

Under current FDA guidance, a 503A pharmacy can compound a GLP-1 medication for a specific patient only when the prescriber documents a "significant difference" - a genuine clinical reason why the compounded formulation serves that patient's specific medical need in a way the commercially available FDA-approved product cannot

Semaglutide GLP-1 should not be taken by pregnant women, people with histories of pancreatitis, thyroid cancer, or multiple endocrine neoplasia syndrome type 2

We always try to detect a small inotropic effect of cilostamide before we add other drugs that act via cAMP and are thus expected to be more effective in the presence of cilostamide